Drug intelligence / Profile preview

Vaxonella

Development stage: Unknown
Lead developer: Prokarium
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Vaxonella is an oral vaccine delivery platform developed by Prokarium that utilizes live, attenuated, genetically modified *Salmonella enterica* serovar Typhi bacteria. The platform is engineered to be safe and serves as a vehicle to deliver recombinant protein vaccines directly to the immune system via the gut lining. It incorporates Emergent BioSolutions' Typhella and spi-VEC technologies alongside Prokarium's proprietary ORT-VAC (Operator-Repressor Titration for Vaccines) plasmid stabilization system, which ensures the maintenance of self-replicating DNA plasmids without the need for antibiotic resistance markers. Vaxonella is designed for high thermostability, remaining stable at 40°C for up to 12 weeks and maintaining a shelf life of over three years at 4°C, which facilitates distribution in regions without reliable cold chain infrastructure. It is being applied to develop vaccines for enteric fever (typhoid and paratyphoid), *Chlamydia*, *Clostridioides difficile*, and other infectious diseases.

Brand names: Vaxonella

Beyond the preview

Go deeper on Vaxonella.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxonella.

Explore the full profile